the major risk factors for CHD. 3, 4 This emphasizes the need for implementing most suitable preventive strategies based on a healthy lifestyle which should be effective to protect against CHD in subjects with risk factors or to prevent secondary incidence in CHD confirmed subjects. Sudden cardiac death (SCD) is the initial clinical coronary event in patients with CHD which contributes to approximately 50% of deaths.
Omega (ω)-3 fatty acids (FAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) level in blood or on the erythrocyte membrane are associated with lowered cardiovascular mortality. [5] [6] [7] The relative risk of SCD in patients after myocardial infarction (MI) was inversely correlated to the blood level of ω-3 FA. 5, 7 Though many randomized clinical trials (RCTs) have concluded the role of EPA plus DHA in reducing the risk or protecting the CHD in high-risk populations, many of the recent trials did not support the beneficial effects. 8 Therefore, the inconsistent results of RCTs demand further well-designed clinical trials in different populations by excluding the possible interfering factors. Hence, an article about the recent updates on the role of ω-3 FA in CHD is needed. This review article discusses the role of EPA/DHA in subjects with CHD.
| EFFEC TS OF OMEG A FAT T Y ACIDS IN CORONARY HE ART DIS E A S E
Arachidonic acid (ARA), a dietary ω-6 FA is metabolized in cyclooxygenase (COX)-1 or -2 pathway to produce series 2 prostanoids and series 4 leukotrienes (LTs) which are considered as more potent pro-inflammatory and pro-thrombolytic agents, while series 3 prostanoids and series 5 leukotrienes synthesized from ω-3 FAs are found less potent in their biological activities. Short-lived series 2 prostanoids such as prostaglandins-E2 and -F2 α increase the synthesis of interleukin (IL)-6, a pro-inflammatory cytokine in macrophages and LTB 4, a chemotactic agent to activates the neutrophils and releases reactive oxygen species. Thromboxanes A2, another series 2 prostanoid, is a potent vasoconstrictor and platelet activator. [9] [10] [11] [12] Furthermore, ARA can directly activate the NADPH oxidase complex in neutrophils, eosinophils and macrophages to release the superoxide anion free radical which can activate the transcription factor, nuclear factor-kappa B (NF-kB), to elicit the synthesis of inflammatory mediators. 13, 14 Another dietary ω-6 FA, linoleic acid (LA)
can enter to the liver microsomal desaturase-elongase pathway to increase the production of ARA and, thus, release the pro-inflammatory cytokines. 15 Nevertheless, the biological effects of metabolites produced from the ω FAs the ratio between dietary ω-6/ω-3 FA determines their selectivity for the metabolic pathways. Supplementation of EPA or DHA will cause a shift of CYP-450 as well as COX/lipoxygenase mediated metabolic pathways from ω-6 FAs that leads to an increased level of their anti-inflammatory epoxy metabolites in tissue and plasma. Therefore, a decreased ω-6/ω-3 ratio is beneficial to suppress the inflammation in chronic diseases. When the diet is supplemented with ω-6 and ω-3 FA in a particular ratio, protection against inflammatory diseases are evidenced. The ARA supplementation neither affected the EPA nor DHA content of serum phospholipids or triacyl glycerol (TAG). 16 However, a diet high in LA is inversely associated with the level of EPA or increases the ARA:EPA ratio.
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A diet with a total ω-6/ω-3 FA in a ratio of 4/1 produced a 70% decreased mortality rate from CVD. 18 While ratio of 2-3/1 could effectively suppress the inflammation in rheumatoid arthritis patients. 18 Dietary and plasma level of EPA and DHA were inversely associated with incidence of CVD. 19 Wang et al 20 A GISSI-Prevenzione trial on 11 324 MI patients when administered with 850 mg of EPA plus DHA (in ratio of 1:2) along with 300 mg vitamin E showed significant reduction in SCD. However, no significant beneficial effect was obtained in patients with stroke or non-fatal MI. 7 The beneficial protective effect from SCD was four fold higher in patients with left ventricular systolic dysfunction. 7, 27 A decreased mortality rate from CHD was evidenced in a Japanese population when they consumed three or more servings of seafood/ week (but not fried). 28 Furthermore, when compared to the subjects with little or no seafood intake, the protection is better for moderate consumers of one to two servings/week. According to Rimm et al, 29 one to two seafood meals per week can reduce the risk of CHF, CHD, ischemic stroke, and SCD.
TA B L E 2 Clinical trials using omega-3 fatty acids showed negative results on mortality ) channel on sarcoplasmic reticulum produces anti-arrhythmic effect. Signalling pathways such as protein kinase (PK) -A and-C, mitogen-activated protein kinase (MAPK) and calcium-dependent calmodulin kinase II(CaCMK) were inhibited. The enhanced endothelial nitric oxide synthase (eNOS) activity produces more NO for the vasorelaxation. Enhanced nuclear erythroid factor-2 (Nrf2) favors the antioxidant status. ROS, reactive oxygen species
The 30 But later studies in patients using 1-2 g ω- 
| PROTEC TIVE MECHANIS MS OF OMEG A-FAT T Y ACIDS
Despite the inconsistent results of various clinical trials (Table 2) 45 EPA could relax the artery through an endothelium-dependent NO release. 46 EPA and DHA supplementation can partially replace the ARA from the cell membrane to alleviate the pro-inflammatory and pro-thrombolytic effects. 47 Major effects of DHA and EPA on various cells are depicted in Figure 2 . Several beneficial effects of ω-3 FA were due to their hydroxy and epoxy derivatives which are involved in the signal transduction pathways. 48, 49 Even at the nanomolar level, than simvastatin alone. 60 Similar observations were also found in mixed dyslipidemic patients. 61 Lipoxygenase pathway can synthesize di-and trihydroxy derivatives of ω-3 FAs which include resolvins (resolving D series from DHA and E series from EPA), maresins (from DHA) and protectins (from DHA). 62 These lipid mediators are involved in natural tissue resolution, controlling neutrophil infiltration into tissue during the acute inflammation and preventing the progression of inflammation. 63 Deficiency of these lipid mediators in CAD can augment damage to the arterial wall. 64 Resolvin D1, D2, maresin and protectin are effective to suppress the release of inflammatory cytokines. Further, they phosphorylate the protein kinase-B and glycogen synthase kinase 3β to exhibit anti-inflammatory effect. 51, 65 Combination of aspirin with ω-3 FAs was found to trigger the synthesis of these lipid mediators and thus enhance the anti-inflammatory activity. 66 
| CON CLUS I ON AND FUTURE PER S PEC TIVE S
Regardless of the dosage used in clinical trials, at least 1 g/d of EPA plus DHA is required to achieve an effective blood level that can render the protection. 67 The American Heart Association recommends consumption of fatty fish at least two times per week for an adult. 68 In the GISSI-Prevenzione trial, CHD patients are advised to take ~1 g of EPA plus DHA per day (Table 3) . Despite these recommendations, many recent results failed to provide such beneficial effects. 69 Moreover, study conducted in men with angina who consumed fish oil capsules showed a higher risk of cardiac death. 70 Determination of the beneficial effect producing blood level of ω-3 FA in various pathological conditions may be considered for a consistent result. 71 The doses of fish oil which are effective to reduce the TAG level and blood pressure did not interfere in the glucose metabolism. 
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